title: Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression.
abstract: YM155, a small-molecule survivin suppressant, specifically binds to the transcription factor ILF3, which regulates the expression of survivin[1]. In this experiment we have demonstrated that p54(nrb) binds to the survivin promoter and regulates survivin expression. p54(nrb) forms a complex with ILF3, which directly binds to YM155. YM155 induces disruption of the ILF3/p54(nrb) complex, which results in a different subcellular localization between ILF3 and p54(nrb). Thus, identification of molecular targets of YM155 in suppression of the survivin pathway, might lead to development of its use as a novel potential target in cancers.
authors: Drug Discovery Research, Astellas Pharma, Inc., Tsukuba-shi, Ibaraki, Japan. tomohiro.yamauchi@astellas.com
authors: Tomohiro
authors: T
authors: Yamauchi
authors: Naoto
authors: N
authors: Nakamura
authors: Masashi
authors: M
authors: Hiramoto
authors: Masatoshi
authors: M
authors: Yuri
authors: Hiroyuki
authors: H
authors: Yokota
authors: Masanori
authors: M
authors: Naitou
authors: Masahiro
authors: M
authors: Takeuchi
authors: Kentaro
authors: K
authors: Yamanaka
authors: Aya
authors: A
authors: Kita
authors: Takahito
authors: T
authors: Nakahara
authors: Isao
authors: I
authors: Kinoyama
authors: Akira
authors: A
authors: Matsuhisa
authors: Naoki
authors: N
authors: Kaneko
authors: Hiroshi
authors: H
authors: Koutoku
authors: Masao
authors: M
authors: Sasamata
authors: Masato
authors: M
authors: Kobori
authors: Masao
authors: M
authors: Katou
authors: Shuichi
authors: S
authors: Tawara
authors: Shigeki
authors: S
authors: Kawabata
authors: Kiyoshi
authors: K
authors: Furuichi
mesh_terms: D021581:Active Transport, Cell Nucleus / Q000187:drug effects; D045744:Cell Line, Tumor; D002466:Cell Nucleolus / Q000378:metabolism; D004268:DNA-Binding Proteins; D050687:E2F1 Transcription Factor / Q000378:metabolism; D050703:E2F2 Transcription Factor / Q000378:metabolism; D057809:HEK293 Cells; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D051034:Inhibitor of Apoptosis Proteins / Q000096:biosynthesis* / Q000235:genetics; D009285:Naphthoquinones / Q000494:pharmacology*; D050779:Nuclear Factor 90 Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D034521:Nuclear Matrix-Associated Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D050810:Octamer Transcription Factors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011401:Promoter Regions, Genetic; D011485:Protein Binding; D016601:RNA-Binding Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000077022:Survivin
chemical_list: C107489:BIRC5 protein, human; D004268:DNA-Binding Proteins; D050687:E2F1 Transcription Factor; C493753:E2F1 protein, human; D050703:E2F2 Transcription Factor; C493761:E2F2 protein, human; C429643:ILF3 protein, human; D007093:Imidazoles; D051034:Inhibitor of Apoptosis Proteins; C083214:NONO protein, human; D009285:Naphthoquinones; D050779:Nuclear Factor 90 Proteins; D034521:Nuclear Matrix-Associated Proteins; D050810:Octamer Transcription Factors; D016601:RNA-Binding Proteins; D000077022:Survivin; C523798:sepantronium